RxDoctor Payments Data

Llewellyn Rowe, MD

Interventional Cardiology · Florence, SCNPI 1801816145

Payments from drug & device makers

$3,370in general payments, 2019–2025

Across 223 payments — averaging $15.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$870
  • Johnson & Johnson$561
  • Pfizer$402
  • Merck$355
  • Boehringer Ingelheim$229
  • Sanofi-aventis U.S. LLC$227
  • plus $726 from 18 others

What the payments were for

  • Food & beverage$3,31498%
  • Education$552%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,370 in reported general payments places this provider in the 15th percentile of 117 interventional cardiology providers in South Carolina.

See all interventional cardiology providers in South Carolina

Medicare billing

Part B allowed, 2024
$447,612
Medicare patients
826
Services billed
6,998

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban244$259,468
EntrestoSacubitril/Valsartan156$208,940
XareltoRivaroxaban135$126,108
Metoprolol Succinate392$6,344
Ranolazine ErRanolazine41$5,414
Losartan Potassium336$5,003
Atorvastatin Calcium312$4,040
Nifedipine ErNifedipine107$2,375
ClopidogrelClopidogrel Bisulfate162$2,101
Rosuvastatin Calcium76$1,992
Nitroglycerin215$1,931
Diltiazem 24hr Er (Cd)Diltiazem Hcl70$1,909
Metoprolol Tartrate272$1,861
Carvedilol225$1,738
Potassium Chloride102$1,642

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$402$259,468244 claims
NovartisEntresto$870$208,940156 claims
Johnson & JohnsonXarelto$561$126,108135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 117 interventional cardiology providers in South Carolina.

Other interventional cardiology in Florence

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →